Abstract:Abstract Abstract 4589 Objective: BAG3, a member of BAG family, is shown to sustain cell survival and underlies resistance to chemotherapy in human cancer cells, through down-modulation of apoptosis. It can also enhance cell adhesion and migration to promote tumoral invasion. However, the role of BAG3 in human chronic lymphatic leukemia (CLL) remains unclear. Our study aims to discover the roles of BAG3 in the apoptosis and migration of primary CLL cells. Method: In our study, Peripheral blood mononuclear cells were freshly isolated from 18 previously untreated patients. The primary CLL cells were cultured for 6 hours, following, three siRNA (siRNA-1, siRNA-2 and siRNA-3) targeting with different regions of BAG3 mRNA and one non-targeting siRNA were transfected into CLL cells by using Lipofectamine 2000. 6 samples were collected for checking the transfection efficiency by real-time PCR and western blot after 24 or 48 hours. The other 6 samples were exposured with or without fludarabine 12 hours later after tansfection; with another 24 or 48 hours, both cells were harvested, stained with annexin V/PI,and then apoptosis were analyzed using a FACSCalibur flow cytometer.on the other hand, transwell assay were performed in another 6 samples 12 hours after tansfection. to analysis cell migration, the cells were collected and counted 24 hours later. Result: By using the siRNA technique, we successfully down-regulated the expression of BAG3 by 3 different siRNAs. BAG3 mRNA was decreased □‘6 folds (p < 0.05). In order to analyze the effect of BAG3 on CLL cell apoptosis, we used flow cytometry to measure cell apoptosis. Here, the apoptosis rates of CLL cells were increased □‘2 folds after 24 hours transfection by siRNA-2 and siRNA-3 (p < 0.05), and □‘2.5 folds after 48 hours transfection by BAG3 siRNA-1, siRNA-2 and siRNA-3 (p < 0.05). These indicate that BAG3 makes an anti-apoptotic, and knocking-down of it increases the cell apoptosis. To assess the role of BAG3 in the migration of CLL, we used transwell assay to measure cell migration. We found that the migration of CLL cells was decreased 28% by BAG3 siRNA-1 treatment (p < 0.05), 47% by siRNA-2 (p < 0.01) and 50% by siRNA-3 (p < 0.01), respectively. These data showed that BAG3 enhances the CLL migration, and down-regulation of it can inhibit cell migration. Furthermore, fludarabine and BAG3 siRNA were co-treated with CLL cells, to check whether knocking-down of BAG3 can reverse the CLL cells’ resistance against fludarabine. However, the apoptosis rates are not different between co-treated cells and fludarabine-treated cells, which indicated knocking-down of BAG3 may not reverse the fludarabine resistance, though it can promote cell apoptosis and inhibit cell migration. Conclusion: Based on these observations, we conclude that BAG3 may be a potential therapeutic target of human CLL, and inhibition of BAG3 expression can induce cell apoptosis and inhibit cell migration. Disclosures: No relevant conflicts of interest to declare.

siRNA-mediated downregulation of BATF3 diminished proliferation and induced apoptosis through downregulating c-Myc expression in chronic myelogenous leukemia cells

Expression and Functions of the STAT3-SCLIP Pathway in Chronic Myeloid Leukemia Cells.

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy.

Inhibition of Stat3 Expression Induces Apoptosis and Suppresses Proliferation in Human Leukemia Hl-60 Cells

MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia

The synergistic effect of miR-203 and cytarabine on the inhibition of cell proliferation and induction of apoptosis in chronic myelogenous leukemia cells

Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

CLPs-miR-103a-2-5p inhibits proliferation and promotes cell apoptosis in AML cells by targeting LILRB3 and Nrf2/HO-1 axis, regulating CD8 + T cell response

The Biological Role of BAG3 in Human Chronic Lymphatic Leukemia

Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB

Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models

Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells]

Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML

RSL3 enhances ROS-mediated cell apoptosis of myelodysplastic syndrome cells through MYB/Bcl-2 signaling pathway

Targeting Bim via a lncRNA Morrbid Regulates the Survival of Preleukemic and Leukemic Cells

Enhanced induction of apoptosis in chronic myeloid leukemia cells through synergistic effect of telomerase inhibitor MST-312 and imatinib

Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia

A Long Noncoding RNA Critically Regulates Bcr-Abl-mediated Cellular Transformation by Acting As a Competitive Endogenous RNA

Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia